Global Subcutaneous Injection

Subcutaneous Injection Comprehensive Study by Type (Devices, Drugs), Application (Diabetes Management (Insulin therapy), Oncology (Cancer treatments using biologics), Autoimmune Diseases (Rheumatoid arthritis, psoriasis, multiple sclerosis), Hormone Replacement Therapy (Growth hormones, testosterone therapy), Pain Management, Allergy Treatment, Vaccination & Immunization), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End User (Hospitals & Clinics, Home Care Settings (Self-administration by patients), Ambulatory Surgical Centers (ASCs), Specialty Clinics) Players and Region - Global Market Outlook to 2032

Subcutaneous Injection Market by XX Submarkets | Forecast Years 2025-2032  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Subcutaneous Injection Market Scope
The subcutaneous injection market is experiencing significant growth, driven by the rising prevalence of chronic diseases such as diabetes, autoimmune disorders, and hormonal deficiencies. Subcutaneous injections are widely used for drug delivery due to their ease of administration, improved patient compliance, and ability to provide sustained drug absorption. The growing preference for self-administration of biologics, particularly in treating conditions like rheumatoid arthritis and multiple sclerosis, has further propelled market expansion. Advancements in drug delivery devices, including prefilled syringes, autoinjectors, and pen injectors, are enhancing patient convenience and reducing the risk of administration errors. Pharmaceutical companies are increasingly focusing on developing biologics and biosimilars that require subcutaneous delivery, creating lucrative opportunities for market players. North America dominates the market due to the high prevalence of diabetes and cancer, the availability of advanced healthcare infrastructure, and strong R&D investments. However, the Asia-Pacific region is expected to witness the fastest growth, driven by an aging population, increasing healthcare access, and rising adoption of biologic therapies. Despite its growth potential, the market faces challenges such as needle phobia, the risk of injection site reactions, and regulatory hurdles associated with new drug-device combinations. Additionally, the high cost of biologic drugs limits accessibility, particularly in developing nations. Nonetheless, the increasing shift toward home healthcare, coupled with technological advancements in needle-free injection systems, is expected to drive sustained market growth. As pharmaceutical and medical device companies continue to innovate, the subcutaneous injection market is poised for significant expansion in the coming years.

AttributesDetails
Study Period2020-2032
Base Year2024
UnitValue (USD Million)
Key Companies ProfiledBecton Dickinson, Daiichi Sankyo, Sanofi, Roche, GSK, Eli Lilly, Asahi Kasei Pharma, Takeda Pharmaceutical, Antares Pharma, Inc., Eisai Co.?Ltd, Chugai Pharmaceutical, Endo International, PenJet Corporation and Aspen Medical Group
CAGR%


Subcutaneous Injection is highly competitive, with several key players dominating the industry. The market players are focused on developing a variety of features and benefits to meet the needs. Thus, constantly introducing new innovation in processing to meet the changing needs and preferences of consumers. The companies are also planning strategic activities like partnerships, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge. Research Analyst at AMA estimates that Global Players will contribute to the maximum growth of Global Subcutaneous Injection market throughout the predicted period.

Becton Dickinson, Daiichi Sankyo, Sanofi, Roche, GSK, Eli Lilly, Asahi Kasei Pharma, Takeda Pharmaceutical, Antares Pharma, Inc., Eisai Co.?Ltd, Chugai Pharmaceutical, Endo International, PenJet Corporation and Aspen Medical Group are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Subcutaneous Injection market by Type , by Application (Diabetes Management (Insulin therapy), Oncology (Cancer treatments using biologics), Autoimmune Diseases (Rheumatoid arthritis, psoriasis, multiple sclerosis), Hormone Replacement Therapy (Growth hormones, testosterone therapy), Pain Management, Allergy Treatment and Vaccination & Immunization) and Region with country level break-up.

On the basis of geography, the market of Subcutaneous Injection has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2024.

Market Leaders and their expansionary development strategies
In November 2204, Ypsomed, a Swiss medical technology company, has secured a contract with Novo Nordisk to supply injection pens for Novo's experimental obesity drug, CagriSema. This partnership reflects Novo's long-term plans for commercial production of its next-generation obesity treatments, with CagriSema showing promising results in late-stage trials. ​
In Spetember 2023, Ypsomed signed a long-term deal with Novo Nordisk to supply autoinjectors for drugs treating metabolic conditions. Novo Nordisk will invest significantly in expanding Ypsomed's manufacturing capacity, with these autoinjectors expected to be available by 2025 for Novo's new GLP-1 drugs currently in clinical trials.


Influencing Trend:
Growing Trend of Self-Administration

Market Growth Drivers:
Prevalence of Chronic Diseases and Increasing Demand for Biologics & Biosimilars

Challenges:
Limited Awareness and Accessibility

Restraints:
High Cost of Subcutaneous Injectors

Opportunities:
Advancements in Biologic Therapies and Innovations in needle-free injectors and smart drug delivery devices enhance market potential.

Key Target Audience
Government Authorities, Research and Development, Investors, Venture Capitalist and Third Party Knowledge Providers

Report Objectives / Segmentation Covered

By Type
  • Devices
  • Drugs
By Application
  • Diabetes Management (Insulin therapy)
  • Oncology (Cancer treatments using biologics)
  • Autoimmune Diseases (Rheumatoid arthritis, psoriasis, multiple sclerosis)
  • Hormone Replacement Therapy (Growth hormones, testosterone therapy)
  • Pain Management
  • Allergy Treatment
  • Vaccination & Immunization
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By End User
  • Hospitals & Clinics
  • Home Care Settings (Self-administration by patients)
  • Ambulatory Surgical Centers (ASCs)
  • Specialty Clinics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Chronic Diseases
      • 3.2.2. Increasing Demand for Biologics & Biosimilars
    • 3.3. Market Challenges
      • 3.3.1. Limited Awareness and Accessibility
    • 3.4. Market Trends
      • 3.4.1. Growing Trend of Self-Administration
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Subcutaneous Injection, by Type, Application, Distribution Channel, End User and Region (value) (2019-2024)
    • 5.1. Introduction
    • 5.2. Global Subcutaneous Injection (Value)
      • 5.2.1. Global Subcutaneous Injection by: Type (Value)
        • 5.2.1.1. Devices
        • 5.2.1.2. Drugs
      • 5.2.2. Global Subcutaneous Injection by: Application (Value)
        • 5.2.2.1. Diabetes Management (Insulin therapy)
        • 5.2.2.2. Oncology (Cancer treatments using biologics)
        • 5.2.2.3. Autoimmune Diseases (Rheumatoid arthritis, psoriasis, multiple sclerosis)
        • 5.2.2.4. Hormone Replacement Therapy (Growth hormones, testosterone therapy)
        • 5.2.2.5. Pain Management
        • 5.2.2.6. Allergy Treatment
        • 5.2.2.7. Vaccination & Immunization
      • 5.2.3. Global Subcutaneous Injection by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online Pharmacies
      • 5.2.4. Global Subcutaneous Injection by: End User (Value)
        • 5.2.4.1. Hospitals & Clinics
        • 5.2.4.2. Home Care Settings (Self-administration by patients)
        • 5.2.4.3. Ambulatory Surgical Centers (ASCs)
        • 5.2.4.4. Specialty Clinics
      • 5.2.5. Global Subcutaneous Injection Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Subcutaneous Injection: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2024)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Becton Dickinson
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Daiichi Sankyo
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Roche
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GSK
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eli Lilly
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Asahi Kasei Pharma
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Takeda Pharmaceutical
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Antares Pharma, Inc.
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Eisai Co.?Ltd
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Chugai Pharmaceutical
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Endo International
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. PenJet Corporation
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Aspen Medical Group
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
  • 7. Global Subcutaneous Injection Sale, by Type, Application, Distribution Channel, End User and Region (value) (2027-2032)
    • 7.1. Introduction
    • 7.2. Global Subcutaneous Injection (Value)
      • 7.2.1. Global Subcutaneous Injection by: Type (Value)
        • 7.2.1.1. Devices
        • 7.2.1.2. Drugs
      • 7.2.2. Global Subcutaneous Injection by: Application (Value)
        • 7.2.2.1. Diabetes Management (Insulin therapy)
        • 7.2.2.2. Oncology (Cancer treatments using biologics)
        • 7.2.2.3. Autoimmune Diseases (Rheumatoid arthritis, psoriasis, multiple sclerosis)
        • 7.2.2.4. Hormone Replacement Therapy (Growth hormones, testosterone therapy)
        • 7.2.2.5. Pain Management
        • 7.2.2.6. Allergy Treatment
        • 7.2.2.7. Vaccination & Immunization
      • 7.2.3. Global Subcutaneous Injection by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online Pharmacies
      • 7.2.4. Global Subcutaneous Injection by: End User (Value)
        • 7.2.4.1. Hospitals & Clinics
        • 7.2.4.2. Home Care Settings (Self-administration by patients)
        • 7.2.4.3. Ambulatory Surgical Centers (ASCs)
        • 7.2.4.4. Specialty Clinics
      • 7.2.5. Global Subcutaneous Injection Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Subcutaneous Injection: by Type(USD Million)
  • Table 2. Subcutaneous Injection Devices , by Region USD Million (2019-2024)
  • Table 3. Subcutaneous Injection Drugs , by Region USD Million (2019-2024)
  • Table 4. Subcutaneous Injection: by Application(USD Million)
  • Table 5. Subcutaneous Injection Diabetes Management (Insulin therapy) , by Region USD Million (2019-2024)
  • Table 6. Subcutaneous Injection Oncology (Cancer treatments using biologics) , by Region USD Million (2019-2024)
  • Table 7. Subcutaneous Injection Autoimmune Diseases (Rheumatoid arthritis, psoriasis, multiple sclerosis) , by Region USD Million (2019-2024)
  • Table 8. Subcutaneous Injection Hormone Replacement Therapy (Growth hormones, testosterone therapy) , by Region USD Million (2019-2024)
  • Table 9. Subcutaneous Injection Pain Management , by Region USD Million (2019-2024)
  • Table 10. Subcutaneous Injection Allergy Treatment , by Region USD Million (2019-2024)
  • Table 11. Subcutaneous Injection Vaccination & Immunization , by Region USD Million (2019-2024)
  • Table 12. Subcutaneous Injection: by Distribution Channel(USD Million)
  • Table 13. Subcutaneous Injection Hospital Pharmacies , by Region USD Million (2019-2024)
  • Table 14. Subcutaneous Injection Retail Pharmacies , by Region USD Million (2019-2024)
  • Table 15. Subcutaneous Injection Online Pharmacies , by Region USD Million (2019-2024)
  • Table 16. Subcutaneous Injection: by End User(USD Million)
  • Table 17. Subcutaneous Injection Hospitals & Clinics , by Region USD Million (2019-2024)
  • Table 18. Subcutaneous Injection Home Care Settings (Self-administration by patients) , by Region USD Million (2019-2024)
  • Table 19. Subcutaneous Injection Ambulatory Surgical Centers (ASCs) , by Region USD Million (2019-2024)
  • Table 20. Subcutaneous Injection Specialty Clinics , by Region USD Million (2019-2024)
  • Table 21. South America Subcutaneous Injection, by Country USD Million (2019-2024)
  • Table 22. South America Subcutaneous Injection, by Type USD Million (2019-2024)
  • Table 23. South America Subcutaneous Injection, by Application USD Million (2019-2024)
  • Table 24. South America Subcutaneous Injection, by Distribution Channel USD Million (2019-2024)
  • Table 25. South America Subcutaneous Injection, by End User USD Million (2019-2024)
  • Table 26. Brazil Subcutaneous Injection, by Type USD Million (2019-2024)
  • Table 27. Brazil Subcutaneous Injection, by Application USD Million (2019-2024)
  • Table 28. Brazil Subcutaneous Injection, by Distribution Channel USD Million (2019-2024)
  • Table 29. Brazil Subcutaneous Injection, by End User USD Million (2019-2024)
  • Table 30. Argentina Subcutaneous Injection, by Type USD Million (2019-2024)
  • Table 31. Argentina Subcutaneous Injection, by Application USD Million (2019-2024)
  • Table 32. Argentina Subcutaneous Injection, by Distribution Channel USD Million (2019-2024)
  • Table 33. Argentina Subcutaneous Injection, by End User USD Million (2019-2024)
  • Table 34. Rest of South America Subcutaneous Injection, by Type USD Million (2019-2024)
  • Table 35. Rest of South America Subcutaneous Injection, by Application USD Million (2019-2024)
  • Table 36. Rest of South America Subcutaneous Injection, by Distribution Channel USD Million (2019-2024)
  • Table 37. Rest of South America Subcutaneous Injection, by End User USD Million (2019-2024)
  • Table 38. Asia Pacific Subcutaneous Injection, by Country USD Million (2019-2024)
  • Table 39. Asia Pacific Subcutaneous Injection, by Type USD Million (2019-2024)
  • Table 40. Asia Pacific Subcutaneous Injection, by Application USD Million (2019-2024)
  • Table 41. Asia Pacific Subcutaneous Injection, by Distribution Channel USD Million (2019-2024)
  • Table 42. Asia Pacific Subcutaneous Injection, by End User USD Million (2019-2024)
  • Table 43. China Subcutaneous Injection, by Type USD Million (2019-2024)
  • Table 44. China Subcutaneous Injection, by Application USD Million (2019-2024)
  • Table 45. China Subcutaneous Injection, by Distribution Channel USD Million (2019-2024)
  • Table 46. China Subcutaneous Injection, by End User USD Million (2019-2024)
  • Table 47. Japan Subcutaneous Injection, by Type USD Million (2019-2024)
  • Table 48. Japan Subcutaneous Injection, by Application USD Million (2019-2024)
  • Table 49. Japan Subcutaneous Injection, by Distribution Channel USD Million (2019-2024)
  • Table 50. Japan Subcutaneous Injection, by End User USD Million (2019-2024)
  • Table 51. India Subcutaneous Injection, by Type USD Million (2019-2024)
  • Table 52. India Subcutaneous Injection, by Application USD Million (2019-2024)
  • Table 53. India Subcutaneous Injection, by Distribution Channel USD Million (2019-2024)
  • Table 54. India Subcutaneous Injection, by End User USD Million (2019-2024)
  • Table 55. South Korea Subcutaneous Injection, by Type USD Million (2019-2024)
  • Table 56. South Korea Subcutaneous Injection, by Application USD Million (2019-2024)
  • Table 57. South Korea Subcutaneous Injection, by Distribution Channel USD Million (2019-2024)
  • Table 58. South Korea Subcutaneous Injection, by End User USD Million (2019-2024)
  • Table 59. Taiwan Subcutaneous Injection, by Type USD Million (2019-2024)
  • Table 60. Taiwan Subcutaneous Injection, by Application USD Million (2019-2024)
  • Table 61. Taiwan Subcutaneous Injection, by Distribution Channel USD Million (2019-2024)
  • Table 62. Taiwan Subcutaneous Injection, by End User USD Million (2019-2024)
  • Table 63. Australia Subcutaneous Injection, by Type USD Million (2019-2024)
  • Table 64. Australia Subcutaneous Injection, by Application USD Million (2019-2024)
  • Table 65. Australia Subcutaneous Injection, by Distribution Channel USD Million (2019-2024)
  • Table 66. Australia Subcutaneous Injection, by End User USD Million (2019-2024)
  • Table 67. Rest of Asia-Pacific Subcutaneous Injection, by Type USD Million (2019-2024)
  • Table 68. Rest of Asia-Pacific Subcutaneous Injection, by Application USD Million (2019-2024)
  • Table 69. Rest of Asia-Pacific Subcutaneous Injection, by Distribution Channel USD Million (2019-2024)
  • Table 70. Rest of Asia-Pacific Subcutaneous Injection, by End User USD Million (2019-2024)
  • Table 71. Europe Subcutaneous Injection, by Country USD Million (2019-2024)
  • Table 72. Europe Subcutaneous Injection, by Type USD Million (2019-2024)
  • Table 73. Europe Subcutaneous Injection, by Application USD Million (2019-2024)
  • Table 74. Europe Subcutaneous Injection, by Distribution Channel USD Million (2019-2024)
  • Table 75. Europe Subcutaneous Injection, by End User USD Million (2019-2024)
  • Table 76. Germany Subcutaneous Injection, by Type USD Million (2019-2024)
  • Table 77. Germany Subcutaneous Injection, by Application USD Million (2019-2024)
  • Table 78. Germany Subcutaneous Injection, by Distribution Channel USD Million (2019-2024)
  • Table 79. Germany Subcutaneous Injection, by End User USD Million (2019-2024)
  • Table 80. France Subcutaneous Injection, by Type USD Million (2019-2024)
  • Table 81. France Subcutaneous Injection, by Application USD Million (2019-2024)
  • Table 82. France Subcutaneous Injection, by Distribution Channel USD Million (2019-2024)
  • Table 83. France Subcutaneous Injection, by End User USD Million (2019-2024)
  • Table 84. Italy Subcutaneous Injection, by Type USD Million (2019-2024)
  • Table 85. Italy Subcutaneous Injection, by Application USD Million (2019-2024)
  • Table 86. Italy Subcutaneous Injection, by Distribution Channel USD Million (2019-2024)
  • Table 87. Italy Subcutaneous Injection, by End User USD Million (2019-2024)
  • Table 88. United Kingdom Subcutaneous Injection, by Type USD Million (2019-2024)
  • Table 89. United Kingdom Subcutaneous Injection, by Application USD Million (2019-2024)
  • Table 90. United Kingdom Subcutaneous Injection, by Distribution Channel USD Million (2019-2024)
  • Table 91. United Kingdom Subcutaneous Injection, by End User USD Million (2019-2024)
  • Table 92. Netherlands Subcutaneous Injection, by Type USD Million (2019-2024)
  • Table 93. Netherlands Subcutaneous Injection, by Application USD Million (2019-2024)
  • Table 94. Netherlands Subcutaneous Injection, by Distribution Channel USD Million (2019-2024)
  • Table 95. Netherlands Subcutaneous Injection, by End User USD Million (2019-2024)
  • Table 96. Rest of Europe Subcutaneous Injection, by Type USD Million (2019-2024)
  • Table 97. Rest of Europe Subcutaneous Injection, by Application USD Million (2019-2024)
  • Table 98. Rest of Europe Subcutaneous Injection, by Distribution Channel USD Million (2019-2024)
  • Table 99. Rest of Europe Subcutaneous Injection, by End User USD Million (2019-2024)
  • Table 100. MEA Subcutaneous Injection, by Country USD Million (2019-2024)
  • Table 101. MEA Subcutaneous Injection, by Type USD Million (2019-2024)
  • Table 102. MEA Subcutaneous Injection, by Application USD Million (2019-2024)
  • Table 103. MEA Subcutaneous Injection, by Distribution Channel USD Million (2019-2024)
  • Table 104. MEA Subcutaneous Injection, by End User USD Million (2019-2024)
  • Table 105. Middle East Subcutaneous Injection, by Type USD Million (2019-2024)
  • Table 106. Middle East Subcutaneous Injection, by Application USD Million (2019-2024)
  • Table 107. Middle East Subcutaneous Injection, by Distribution Channel USD Million (2019-2024)
  • Table 108. Middle East Subcutaneous Injection, by End User USD Million (2019-2024)
  • Table 109. Africa Subcutaneous Injection, by Type USD Million (2019-2024)
  • Table 110. Africa Subcutaneous Injection, by Application USD Million (2019-2024)
  • Table 111. Africa Subcutaneous Injection, by Distribution Channel USD Million (2019-2024)
  • Table 112. Africa Subcutaneous Injection, by End User USD Million (2019-2024)
  • Table 113. North America Subcutaneous Injection, by Country USD Million (2019-2024)
  • Table 114. North America Subcutaneous Injection, by Type USD Million (2019-2024)
  • Table 115. North America Subcutaneous Injection, by Application USD Million (2019-2024)
  • Table 116. North America Subcutaneous Injection, by Distribution Channel USD Million (2019-2024)
  • Table 117. North America Subcutaneous Injection, by End User USD Million (2019-2024)
  • Table 118. United States Subcutaneous Injection, by Type USD Million (2019-2024)
  • Table 119. United States Subcutaneous Injection, by Application USD Million (2019-2024)
  • Table 120. United States Subcutaneous Injection, by Distribution Channel USD Million (2019-2024)
  • Table 121. United States Subcutaneous Injection, by End User USD Million (2019-2024)
  • Table 122. Canada Subcutaneous Injection, by Type USD Million (2019-2024)
  • Table 123. Canada Subcutaneous Injection, by Application USD Million (2019-2024)
  • Table 124. Canada Subcutaneous Injection, by Distribution Channel USD Million (2019-2024)
  • Table 125. Canada Subcutaneous Injection, by End User USD Million (2019-2024)
  • Table 126. Mexico Subcutaneous Injection, by Type USD Million (2019-2024)
  • Table 127. Mexico Subcutaneous Injection, by Application USD Million (2019-2024)
  • Table 128. Mexico Subcutaneous Injection, by Distribution Channel USD Million (2019-2024)
  • Table 129. Mexico Subcutaneous Injection, by End User USD Million (2019-2024)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Subcutaneous Injection: by Type(USD Million)
  • Table 145. Subcutaneous Injection Devices , by Region USD Million (2027-2032)
  • Table 146. Subcutaneous Injection Drugs , by Region USD Million (2027-2032)
  • Table 147. Subcutaneous Injection: by Application(USD Million)
  • Table 148. Subcutaneous Injection Diabetes Management (Insulin therapy) , by Region USD Million (2027-2032)
  • Table 149. Subcutaneous Injection Oncology (Cancer treatments using biologics) , by Region USD Million (2027-2032)
  • Table 150. Subcutaneous Injection Autoimmune Diseases (Rheumatoid arthritis, psoriasis, multiple sclerosis) , by Region USD Million (2027-2032)
  • Table 151. Subcutaneous Injection Hormone Replacement Therapy (Growth hormones, testosterone therapy) , by Region USD Million (2027-2032)
  • Table 152. Subcutaneous Injection Pain Management , by Region USD Million (2027-2032)
  • Table 153. Subcutaneous Injection Allergy Treatment , by Region USD Million (2027-2032)
  • Table 154. Subcutaneous Injection Vaccination & Immunization , by Region USD Million (2027-2032)
  • Table 155. Subcutaneous Injection: by Distribution Channel(USD Million)
  • Table 156. Subcutaneous Injection Hospital Pharmacies , by Region USD Million (2027-2032)
  • Table 157. Subcutaneous Injection Retail Pharmacies , by Region USD Million (2027-2032)
  • Table 158. Subcutaneous Injection Online Pharmacies , by Region USD Million (2027-2032)
  • Table 159. Subcutaneous Injection: by End User(USD Million)
  • Table 160. Subcutaneous Injection Hospitals & Clinics , by Region USD Million (2027-2032)
  • Table 161. Subcutaneous Injection Home Care Settings (Self-administration by patients) , by Region USD Million (2027-2032)
  • Table 162. Subcutaneous Injection Ambulatory Surgical Centers (ASCs) , by Region USD Million (2027-2032)
  • Table 163. Subcutaneous Injection Specialty Clinics , by Region USD Million (2027-2032)
  • Table 164. South America Subcutaneous Injection, by Country USD Million (2027-2032)
  • Table 165. South America Subcutaneous Injection, by Type USD Million (2027-2032)
  • Table 166. South America Subcutaneous Injection, by Application USD Million (2027-2032)
  • Table 167. South America Subcutaneous Injection, by Distribution Channel USD Million (2027-2032)
  • Table 168. South America Subcutaneous Injection, by End User USD Million (2027-2032)
  • Table 169. Brazil Subcutaneous Injection, by Type USD Million (2027-2032)
  • Table 170. Brazil Subcutaneous Injection, by Application USD Million (2027-2032)
  • Table 171. Brazil Subcutaneous Injection, by Distribution Channel USD Million (2027-2032)
  • Table 172. Brazil Subcutaneous Injection, by End User USD Million (2027-2032)
  • Table 173. Argentina Subcutaneous Injection, by Type USD Million (2027-2032)
  • Table 174. Argentina Subcutaneous Injection, by Application USD Million (2027-2032)
  • Table 175. Argentina Subcutaneous Injection, by Distribution Channel USD Million (2027-2032)
  • Table 176. Argentina Subcutaneous Injection, by End User USD Million (2027-2032)
  • Table 177. Rest of South America Subcutaneous Injection, by Type USD Million (2027-2032)
  • Table 178. Rest of South America Subcutaneous Injection, by Application USD Million (2027-2032)
  • Table 179. Rest of South America Subcutaneous Injection, by Distribution Channel USD Million (2027-2032)
  • Table 180. Rest of South America Subcutaneous Injection, by End User USD Million (2027-2032)
  • Table 181. Asia Pacific Subcutaneous Injection, by Country USD Million (2027-2032)
  • Table 182. Asia Pacific Subcutaneous Injection, by Type USD Million (2027-2032)
  • Table 183. Asia Pacific Subcutaneous Injection, by Application USD Million (2027-2032)
  • Table 184. Asia Pacific Subcutaneous Injection, by Distribution Channel USD Million (2027-2032)
  • Table 185. Asia Pacific Subcutaneous Injection, by End User USD Million (2027-2032)
  • Table 186. China Subcutaneous Injection, by Type USD Million (2027-2032)
  • Table 187. China Subcutaneous Injection, by Application USD Million (2027-2032)
  • Table 188. China Subcutaneous Injection, by Distribution Channel USD Million (2027-2032)
  • Table 189. China Subcutaneous Injection, by End User USD Million (2027-2032)
  • Table 190. Japan Subcutaneous Injection, by Type USD Million (2027-2032)
  • Table 191. Japan Subcutaneous Injection, by Application USD Million (2027-2032)
  • Table 192. Japan Subcutaneous Injection, by Distribution Channel USD Million (2027-2032)
  • Table 193. Japan Subcutaneous Injection, by End User USD Million (2027-2032)
  • Table 194. India Subcutaneous Injection, by Type USD Million (2027-2032)
  • Table 195. India Subcutaneous Injection, by Application USD Million (2027-2032)
  • Table 196. India Subcutaneous Injection, by Distribution Channel USD Million (2027-2032)
  • Table 197. India Subcutaneous Injection, by End User USD Million (2027-2032)
  • Table 198. South Korea Subcutaneous Injection, by Type USD Million (2027-2032)
  • Table 199. South Korea Subcutaneous Injection, by Application USD Million (2027-2032)
  • Table 200. South Korea Subcutaneous Injection, by Distribution Channel USD Million (2027-2032)
  • Table 201. South Korea Subcutaneous Injection, by End User USD Million (2027-2032)
  • Table 202. Taiwan Subcutaneous Injection, by Type USD Million (2027-2032)
  • Table 203. Taiwan Subcutaneous Injection, by Application USD Million (2027-2032)
  • Table 204. Taiwan Subcutaneous Injection, by Distribution Channel USD Million (2027-2032)
  • Table 205. Taiwan Subcutaneous Injection, by End User USD Million (2027-2032)
  • Table 206. Australia Subcutaneous Injection, by Type USD Million (2027-2032)
  • Table 207. Australia Subcutaneous Injection, by Application USD Million (2027-2032)
  • Table 208. Australia Subcutaneous Injection, by Distribution Channel USD Million (2027-2032)
  • Table 209. Australia Subcutaneous Injection, by End User USD Million (2027-2032)
  • Table 210. Rest of Asia-Pacific Subcutaneous Injection, by Type USD Million (2027-2032)
  • Table 211. Rest of Asia-Pacific Subcutaneous Injection, by Application USD Million (2027-2032)
  • Table 212. Rest of Asia-Pacific Subcutaneous Injection, by Distribution Channel USD Million (2027-2032)
  • Table 213. Rest of Asia-Pacific Subcutaneous Injection, by End User USD Million (2027-2032)
  • Table 214. Europe Subcutaneous Injection, by Country USD Million (2027-2032)
  • Table 215. Europe Subcutaneous Injection, by Type USD Million (2027-2032)
  • Table 216. Europe Subcutaneous Injection, by Application USD Million (2027-2032)
  • Table 217. Europe Subcutaneous Injection, by Distribution Channel USD Million (2027-2032)
  • Table 218. Europe Subcutaneous Injection, by End User USD Million (2027-2032)
  • Table 219. Germany Subcutaneous Injection, by Type USD Million (2027-2032)
  • Table 220. Germany Subcutaneous Injection, by Application USD Million (2027-2032)
  • Table 221. Germany Subcutaneous Injection, by Distribution Channel USD Million (2027-2032)
  • Table 222. Germany Subcutaneous Injection, by End User USD Million (2027-2032)
  • Table 223. France Subcutaneous Injection, by Type USD Million (2027-2032)
  • Table 224. France Subcutaneous Injection, by Application USD Million (2027-2032)
  • Table 225. France Subcutaneous Injection, by Distribution Channel USD Million (2027-2032)
  • Table 226. France Subcutaneous Injection, by End User USD Million (2027-2032)
  • Table 227. Italy Subcutaneous Injection, by Type USD Million (2027-2032)
  • Table 228. Italy Subcutaneous Injection, by Application USD Million (2027-2032)
  • Table 229. Italy Subcutaneous Injection, by Distribution Channel USD Million (2027-2032)
  • Table 230. Italy Subcutaneous Injection, by End User USD Million (2027-2032)
  • Table 231. United Kingdom Subcutaneous Injection, by Type USD Million (2027-2032)
  • Table 232. United Kingdom Subcutaneous Injection, by Application USD Million (2027-2032)
  • Table 233. United Kingdom Subcutaneous Injection, by Distribution Channel USD Million (2027-2032)
  • Table 234. United Kingdom Subcutaneous Injection, by End User USD Million (2027-2032)
  • Table 235. Netherlands Subcutaneous Injection, by Type USD Million (2027-2032)
  • Table 236. Netherlands Subcutaneous Injection, by Application USD Million (2027-2032)
  • Table 237. Netherlands Subcutaneous Injection, by Distribution Channel USD Million (2027-2032)
  • Table 238. Netherlands Subcutaneous Injection, by End User USD Million (2027-2032)
  • Table 239. Rest of Europe Subcutaneous Injection, by Type USD Million (2027-2032)
  • Table 240. Rest of Europe Subcutaneous Injection, by Application USD Million (2027-2032)
  • Table 241. Rest of Europe Subcutaneous Injection, by Distribution Channel USD Million (2027-2032)
  • Table 242. Rest of Europe Subcutaneous Injection, by End User USD Million (2027-2032)
  • Table 243. MEA Subcutaneous Injection, by Country USD Million (2027-2032)
  • Table 244. MEA Subcutaneous Injection, by Type USD Million (2027-2032)
  • Table 245. MEA Subcutaneous Injection, by Application USD Million (2027-2032)
  • Table 246. MEA Subcutaneous Injection, by Distribution Channel USD Million (2027-2032)
  • Table 247. MEA Subcutaneous Injection, by End User USD Million (2027-2032)
  • Table 248. Middle East Subcutaneous Injection, by Type USD Million (2027-2032)
  • Table 249. Middle East Subcutaneous Injection, by Application USD Million (2027-2032)
  • Table 250. Middle East Subcutaneous Injection, by Distribution Channel USD Million (2027-2032)
  • Table 251. Middle East Subcutaneous Injection, by End User USD Million (2027-2032)
  • Table 252. Africa Subcutaneous Injection, by Type USD Million (2027-2032)
  • Table 253. Africa Subcutaneous Injection, by Application USD Million (2027-2032)
  • Table 254. Africa Subcutaneous Injection, by Distribution Channel USD Million (2027-2032)
  • Table 255. Africa Subcutaneous Injection, by End User USD Million (2027-2032)
  • Table 256. North America Subcutaneous Injection, by Country USD Million (2027-2032)
  • Table 257. North America Subcutaneous Injection, by Type USD Million (2027-2032)
  • Table 258. North America Subcutaneous Injection, by Application USD Million (2027-2032)
  • Table 259. North America Subcutaneous Injection, by Distribution Channel USD Million (2027-2032)
  • Table 260. North America Subcutaneous Injection, by End User USD Million (2027-2032)
  • Table 261. United States Subcutaneous Injection, by Type USD Million (2027-2032)
  • Table 262. United States Subcutaneous Injection, by Application USD Million (2027-2032)
  • Table 263. United States Subcutaneous Injection, by Distribution Channel USD Million (2027-2032)
  • Table 264. United States Subcutaneous Injection, by End User USD Million (2027-2032)
  • Table 265. Canada Subcutaneous Injection, by Type USD Million (2027-2032)
  • Table 266. Canada Subcutaneous Injection, by Application USD Million (2027-2032)
  • Table 267. Canada Subcutaneous Injection, by Distribution Channel USD Million (2027-2032)
  • Table 268. Canada Subcutaneous Injection, by End User USD Million (2027-2032)
  • Table 269. Mexico Subcutaneous Injection, by Type USD Million (2027-2032)
  • Table 270. Mexico Subcutaneous Injection, by Application USD Million (2027-2032)
  • Table 271. Mexico Subcutaneous Injection, by Distribution Channel USD Million (2027-2032)
  • Table 272. Mexico Subcutaneous Injection, by End User USD Million (2027-2032)
  • Table 273. Research Programs/Design for This Report
  • Table 274. Key Data Information from Secondary Sources
  • Table 275. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Subcutaneous Injection: by Type USD Million (2019-2024)
  • Figure 5. Global Subcutaneous Injection: by Application USD Million (2019-2024)
  • Figure 6. Global Subcutaneous Injection: by Distribution Channel USD Million (2019-2024)
  • Figure 7. Global Subcutaneous Injection: by End User USD Million (2019-2024)
  • Figure 8. South America Subcutaneous Injection Share (%), by Country
  • Figure 9. Asia Pacific Subcutaneous Injection Share (%), by Country
  • Figure 10. Europe Subcutaneous Injection Share (%), by Country
  • Figure 11. MEA Subcutaneous Injection Share (%), by Country
  • Figure 12. North America Subcutaneous Injection Share (%), by Country
  • Figure 13. Global Subcutaneous Injection share by Players 2024 (%)
  • Figure 14. Global Subcutaneous Injection share by Players (Top 3) 2024(%)
  • Figure 15. Global Subcutaneous Injection share by Players (Top 5) 2024(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Becton Dickinson Revenue, Net Income and Gross profit
  • Figure 18. Becton Dickinson Revenue: by Geography 2024
  • Figure 19. Daiichi Sankyo Revenue, Net Income and Gross profit
  • Figure 20. Daiichi Sankyo Revenue: by Geography 2024
  • Figure 21. Sanofi Revenue, Net Income and Gross profit
  • Figure 22. Sanofi Revenue: by Geography 2024
  • Figure 23. Roche Revenue, Net Income and Gross profit
  • Figure 24. Roche Revenue: by Geography 2024
  • Figure 25. GSK Revenue, Net Income and Gross profit
  • Figure 26. GSK Revenue: by Geography 2024
  • Figure 27. Eli Lilly Revenue, Net Income and Gross profit
  • Figure 28. Eli Lilly Revenue: by Geography 2024
  • Figure 29. Asahi Kasei Pharma Revenue, Net Income and Gross profit
  • Figure 30. Asahi Kasei Pharma Revenue: by Geography 2024
  • Figure 31. Takeda Pharmaceutical Revenue, Net Income and Gross profit
  • Figure 32. Takeda Pharmaceutical Revenue: by Geography 2024
  • Figure 33. Antares Pharma, Inc. Revenue, Net Income and Gross profit
  • Figure 34. Antares Pharma, Inc. Revenue: by Geography 2024
  • Figure 35. Eisai Co.?Ltd Revenue, Net Income and Gross profit
  • Figure 36. Eisai Co.?Ltd Revenue: by Geography 2024
  • Figure 37. Chugai Pharmaceutical Revenue, Net Income and Gross profit
  • Figure 38. Chugai Pharmaceutical Revenue: by Geography 2024
  • Figure 39. Endo International Revenue, Net Income and Gross profit
  • Figure 40. Endo International Revenue: by Geography 2024
  • Figure 41. PenJet Corporation Revenue, Net Income and Gross profit
  • Figure 42. PenJet Corporation Revenue: by Geography 2024
  • Figure 43. Aspen Medical Group Revenue, Net Income and Gross profit
  • Figure 44. Aspen Medical Group Revenue: by Geography 2024
  • Figure 45. Global Subcutaneous Injection: by Type USD Million (2027-2032)
  • Figure 46. Global Subcutaneous Injection: by Application USD Million (2027-2032)
  • Figure 47. Global Subcutaneous Injection: by Distribution Channel USD Million (2027-2032)
  • Figure 48. Global Subcutaneous Injection: by End User USD Million (2027-2032)
  • Figure 49. South America Subcutaneous Injection Share (%), by Country
  • Figure 50. Asia Pacific Subcutaneous Injection Share (%), by Country
  • Figure 51. Europe Subcutaneous Injection Share (%), by Country
  • Figure 52. MEA Subcutaneous Injection Share (%), by Country
  • Figure 53. North America Subcutaneous Injection Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Becton Dickinson
  • Daiichi Sankyo
  • Sanofi
  • Roche
  • GSK
  • Eli Lilly
  • Asahi Kasei Pharma
  • Takeda Pharmaceutical
  • Antares Pharma, Inc.
  • Eisai Co.?Ltd
  • Chugai Pharmaceutical
  • Endo International
  • PenJet Corporation
  • Aspen Medical Group
Select User Access Type

Key Highlights of Report


Mar 2025 227 Pages 93 Tables Base Year: 2024 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Subcutaneous Injection Quantitative research analysis
Global Subcutaneous Injection Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Subcutaneous Injection Market are by type [Devices and Drugs], by end use application [Diabetes Management (Insulin therapy), Oncology (Cancer treatments using biologics), Autoimmune Diseases (Rheumatoid arthritis, psoriasis, multiple sclerosis), Hormone Replacement Therapy (Growth hormones, testosterone therapy), Pain Management, Allergy Treatment and Vaccination & Immunization].
The Subcutaneous Injection Market is gaining popularity and expected to see strong valuation by 2032.
  • Prevalence of Chronic Diseases
  • Increasing Demand for Biologics & Biosimilars

Know More About Global Subcutaneous Injection Report?

Have a Query? Click Here

Other Related Reports

Ophthalmic Surgical Technologies Comprehensive Study by Type (Excimer Laser Systems, Femtosecond Systems, Laser Ophthalmic Surgical Systems, Ophthalmic Surgical Systems, YAG Laser Systems), Surgery T...
$ 3650
Cryotherapy Chambers Comprehensive Study by Type (Cryotherapy Chambers, Cryochamber with cool retention effect, Cryobarrel (cryosauna), Cryochamber), Application (Surgical Applications {Oncology, Car...
$ 3800
Hospital EMR Systems Comprehensive Study by Type (General EMR, Specialty EMR), Application (Clinical Application, Administrative Application, Reporting in Healthcare System, Healthcare Financing, Cli...
$ 3750
Ophthalmic Equipment Comprehensive Study by Type (Diagnostic and Monitoring Equipment, Cataract Surgical Equipment, Glaucoma Surgical Equipment, Refractive Surgical Equipment, Vitreoretinal Surgical ...
$ 3750
Baby Nose Cleaner Comprehensive Study by Type (Pump Nasal Suction Nose Cleaner, Vacuum Suction Nose Cleaner, Electrical Nose Cleaner), Application (3-6 Months, 7-12 Months, 13-24 Months), Distributio...
$ 3350
Laminar Flow Hoods for Laboratories Comprehensive Study by Type (Horizontal, Vertical), Application (Medical, Pharmaceutical, Electronic, Industrial Sectors, Laboratory Research, Others), Components ...
$ 3650